Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors

The Lancet Oncology

Volumn 10, Issue 7, 2009, Pages 709-717

  Karamouzis, Michalis V ^a   Konstantinopoulos, Panagiotis A ^a,b   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AMG 102; ARQ 197; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; JNJ 38877605; K 252A; L 2G7; LAPATINIB; MEMBRANE RECEPTOR; MESENCHYMAL EPITHELIAL TRANSITION FACTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AMG 102; MONOCLONAL ANTIBODY DN 30; MONOCLONAL ANTIBODY L2G7; MONOCLONAL ANTIBODY OA 5D5; MP 470; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; ONCOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; SGX 523; TRANSFORMING PROTEIN; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; XL 880;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER INVASION; CANCER RESISTANCE; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CROSS REACTION; DRUG MECHANISM; DRUG TARGETING; HUMAN; METASTASIS; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR;

EID: 67649365635     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70137-8     Document Type: Review

References (75)

1. Karamouzis M.V., Grandis J.R., and Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 298 (2007) 70-82
2. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357 (2007) 39-51
3. Taulli R., Scuoppo C., Bersani F., et al. Validation of MET as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 66 (2006) 4742-4749
4. Lutterbach B., Zeng Q., Davis L.J., et al. Lung cancer cell lines harboring MET gene amplification are dependent on MET for growth and survival. Cancer Res 67 (2007) 2081-2088
5. Shattuck D.L., Miller J.K., Carraway K.L., and Sweeney C. MET receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68 (2008) 1471-1477
6. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007) 1039-1043
7. Stommel J.M., Kimmelman A.C., Ying H., et al. Coactivation of receptor tyrosine kinases affects the response of tumour cells to targeted therapies. Science 318 (2007) 287-290
8. Cooper C.S., Park M., Blair D.G., et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311 (1984) 29-33
9. Giordano S., Ponzetto C., Di Renzo M.F., Cooper C.S., and Comoglio P.M. Tyrosine kinase receptor indistinguishable from the c-MET protein. Nature 339 (1989) 155-156
10. Naldini L., Vigna E., Narsimhan R.P., et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the prot-oncogene c-MET. Oncogene 6 (1991) 501-504
11. Chmielowiec J., Borowiak M., Morkel M., et al. c-MET is essential for wound healing in the skin. J Cell Biol 177 (2007) 151-162
12. Paranjpe S., Bowen W.C., Bell A.W., Nejak-Bowen K., Luo J.H., and Michalopoulos G.K. Cell cycle effects resulting from inhibition of hepatocyte growth factor and its receptor c-MET in regenerating rat livers by RNA interference. Hepatology 45 (2007) 1471-1477
13. Peschard P., Fournier T.M., Lamorte L., et al. Mutation of the c-Cbl TKB domain binding site on the MET receptor tyrosine kinase converts it into a transforming protein. Mol Cell 8 (2001) 995-1004
14. Ponzetto C., Bardelli A., Zhen Z., et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77 (1994) 261-271
15. Gentile A., Trusolino L., and Comoglio P.M. The MET tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 27 (2008) 85-94
16. Gual P., Giordano S., Anguissola S., Parker P.J., and Comoglio P.M. Gab1 phosphorylation: a novel mechanism for negative regulation of HGF receptor signaling. Oncogene 20 (2001) 156-166
17. Karamouzis M.V., Konstantinopoulos P.A., and Papavassiliou A.G. The role of STATs in lung carcinogenesis: an emerging target for novel therapeutics. J Mol Med 85 (2007) 427-436
18. Kermorgant S., and Parker P.J. Receptor trafficking controls weak signal delivery: a strategy used by c-MET for STAT3 nuclear accumulation. J Cell Biol 182 (2008) 855-863
19. Konstantinopoulos P.A., Karamouzis M.V., and Papavassiliou A.G. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 6 (2007) 541-555
20. Palka H.L., Park M., and Tonks N.K. Hepatocyte growth factor receptor tyrosine kinase MET is a substrate of the receptor protein-tyrosine phosphatase DEP-1. J Biol Chem 278 (2003) 5728-5735
21. Sangwan V., Paliouras G.N., Cheng A., Dube N., Tremblay M.L., and Park M. Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure. J Biol Chem 281 (2006) 221-228
22. Machide M., Hashigasako A., Matsumoto K., and Nakamura T. Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase. J Biol Chem 281 (2006) 8765-8772
23. Sanchez-Garcia I. The crossroads of oncogenesis and metastasis. N Engl J Med 360 (2009) 297-299
24. Corso S., Migliore C., Ghiso E., De Rosa G., Comoglio P.M., and Giordano S. Silencing the MET oncogene leads to regression of experimental tumours and metastases. Oncogene 27 (2008) 684-693
25. Schmidt L., Junker K., Nakaigawa N., et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18 (1999) 2343-2350
26. Comoglio P.M., Giordano S., and Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7 (2008) 504-516
27. Ivan M., Bond J.A., Prat M., Comoglio P.M., and Wynford-Thomas D. Activated ras and ret oncogenes induce over-expression of c-MET (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 14 (1997) 2417-2423
28. Patil M.A., Lee S.A., Macias E., et al. Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. Cancer Res 69 (2009) 253-261
29. Kanteti R., Nallasura V., Loganathan S., et al. PAX5 is expressed in small-cell lung cancer and positively regulates c-MET transcription. Lab Invest 89 (2009) 301-314
30. Stein U., Walther W., Arlt F., et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 15 (2009) 59-67
31. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., and Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the MET protooncogene. Cancer Cell 3 (2003) 347-361
32. Migliore C., Petrelli A., Ghiso E., et al. MicroRNAs impair MET-mediated invasive growth. Cancer Res 68 (2008) 10128-10136
33. Lu Y., Yao H.P., and Wang M.H. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumourigenic activities, and potential drug targets. Cancer Lett 257 (2007) 157-164
34. Wagh P.K., Peace B.E., and Waltz S.E. Met-related receptor tyrosine kinase Ron in tumour growth and metastasis. Adv Cancer Res 100 (2008) 1-33
35. Follenzi A., Bakovic S., Gual P., Stella M.C., Longati P., and Comoglio P.M. Cross-talk between the proto-oncogenes MET and Ron. Oncogene 19 (2000) 3041-3049
36. Jo M., Stolz D.B., Esplen J.E., Dorko K., Michalopoulos G.K., and Strom S.C. Cross-talk between epidermal growth factor receptor and c-MET signal pathways in transformed cells. J Biol Chem 275 (2000) 8806-8811
37. Wheeler D.L., Huang S., Kruser T.J., et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27 (2001) 3944-3956
38. Bachleither-Hofmann T., Sun M.Y., Chen C.T., et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 7 (2008) 3499-3508
39. Fischer O.M., Giordano S., Comoglio P.M., and Ullrich A. Reactive oxygen species mediate MET receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem 279 (2004) 28970-28978
40. Khoury H., Naujokas M.A., Zuo D., et al. HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell 16 (2005) 550-561
41. Karamouzis M.V., Konstantinopoulos P.A., and Papavassiliou A.G. Trastuzumab-mechanism of action and use. N Engl J Med 357 (2007) 1664
42. Matsumoto K., Nakamura T., and Sakai K. Hepatocyte growth factor and MET in tumour biology and therapeutic approach with NK4. Proteomics 8 (2008) 3360-3370
43. Kim K.J., Wang L., Su Y.C., et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 12 (2006) 1292-1298
44. Jun H.T., Sun J., Rex K., et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 13 (2007) 6735-6742
45. Stabile L.P., Rothstein M.E., Keohavong P., et al. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumourigenesis. Mol Cancer Ther 7 (2008) 1913-1922
46. Mazzone M., Basilico C., Cavassa S., et al. An uncleavable form of pro-scatter factor suppresses tumour growth and dissemination in mice. J Clin Invest 114 (2004) 1418-1432
47. Petrelli A., Circosta P., Granziero L., et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci USA 103 (2006) 5090-5095
48. Martens T., Schmidt N.O., Eckerich C., et al. A novel one-armed anti-c-MET antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12 (2006) 6144-6152
49. Kong-Beltran M., Stamos J., and Wickramasinghe D. The Sema domain of MET is necessary for receptor dimerization and activation. Cancer Cell 6 (2004) 75-84
50. Atabey N., Gao Y., Yao Z.J., et al. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J Biol Chem 276 (2001) 14308-14314
51. O'Toole J.M., Rabenau K.E., Burns K., et al. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 66 (2006) 9162-9170
52. Zhang Y., Kaplan-Lefko P.J., Rex K., et al. Identification of a novel recepteur d'origine nantais/c-MET small-molecule kinase inhibitor with antitumour activity in vivo. Cancer Res 68 (2008) 6680-6687
53. Chan G.K., Lutterbach B.A., Pan B.S., Kariv I., and Szewczak A.A. High-throughput analysis of HGF-stimulated cell scattering. J Biomol Screen 13 (2008) 847-854
54. Patane S., Pietrancosta N., Hassani H., et al. A new MET inhibitory-scaffold identified by a focused forward chemical biological screen. Biochem Biophys Res Commun 375 (2008) 184-189
55. Stabile L.P., Lyker J.S., Huang L., and Siegfried J.M. Inhibition of human non-small cell lung tumours by a c-MET antisense/U6 expression plasmid strategy. Gene Ther 11 (2004) 325-335
56. Kim S.J., Johnson M., Koterba K., Herynk M.H., Uehara H., and Gallick G.E. Reduced c-MET expression by an adenovirus expressing a c-MET ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumour cells in an orthotopic nude mouse model. Clin Cancer Res 9 (2003) 5161-5170
57. Chu S., Feng D., Zhang H., et al. c-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro. J Neurooncol 93 (2009) 183-189
58. Morgillo F., Bareschino M.A., Bianco R., Tortora G., and Ciardiello F. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation 75 (2007) 788-799
59. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
60. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
61. Kobayashi S., Boggon T.J., Dayaram T., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352 (2005) 786-792
62. Balak M.N., Gong Y., Riely G.J., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12 (2006) 6494-6501
63. Noro R., Gemma A., Kosaihira S., et al. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer 6 (2006) 277
64. Sergina N.V., Rausch M., Wang D., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445 (2007) 437-441
65. Linardou H., Dahabreh I.J., Kanaloupiti D., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9 (2008) 962-972
66. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26 (2008) 5705-5712
67. Zucali P.A., Ruiz M.G., Giovannetti E., et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 19 (2008) 1605-1612
68. Tang Z., Du R., Jiang S., et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 99 (2008) 911-922
69. Okabe T., Okamoto I., Tsukioka S., et al. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin Cancer Res 15 (2009) 907-913
70. Lal B., Xia S., Abounader R., and Laterra J. Targeting the c-MET pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res 11 (2005) 4479-4486
71. Kong D.S., Song S.Y., Kim D.H., et al. Prognostic significance of c-MET expression in glioblastomas. Cancer 115 (2008) 140-148
72. Badra F.A., Karamouzis M.V., Ravazoula P., et al. Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and epidermal growth factor receptor (EGFR) family expression. Cancer Lett 244 (2006) 34-41
73. Citri A., and Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7 (2006) 505-516
74. Menendez J.A., Mehmi I., and Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol 24 (2006) 3735-3746
75. de Alava E., Ocana A., Abad M., et al. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol 25 (2007) 2656-2663